- Home
- IFRX vs BETR Comparison
IFRX vs BETR Comparison
Compare IFRX & BETR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- BETR
- Stock Information
- Founded
- IFRX 2007
- BETR 2014
- Country
- IFRX Germany
- BETR United States
- Employees
- IFRX N/A
- BETR N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- BETR Finance: Consumer Services
- Sector
- IFRX Health Care
- BETR Finance
- Exchange
- IFRX Nasdaq
- BETR Nasdaq
- Market Cap
- IFRX 143.7M
- BETR 156.5M
- IPO Year
- IFRX 2017
- BETR N/A
- Fundamental
- Price
- IFRX $2.24
- BETR $10.33
- Analyst Decision
- IFRX Strong Buy
- BETR
- Analyst Count
- IFRX 1
- BETR 0
- Target Price
- IFRX $8.00
- BETR N/A
- AVG Volume (30 Days)
- IFRX 401.6K
- BETR 36.8K
- Earning Date
- IFRX 11-08-2024
- BETR 11-13-2024
- Dividend Yield
- IFRX N/A
- BETR N/A
- EPS Growth
- IFRX N/A
- BETR N/A
- EPS
- IFRX N/A
- BETR N/A
- Revenue
- IFRX $187,930.00
- BETR $85,783,000.00
- Revenue This Year
- IFRX $435.15
- BETR N/A
- Revenue Next Year
- IFRX $180.44
- BETR N/A
- P/E Ratio
- IFRX N/A
- BETR N/A
- Revenue Growth
- IFRX 177.12
- BETR N/A
- 52 Week Low
- IFRX $1.17
- BETR $9.50
- 52 Week High
- IFRX $2.82
- BETR $45.50
- Technical
- Relative Strength Index (RSI)
- IFRX 52.76
- BETR 30.93
- Support Level
- IFRX $1.93
- BETR $9.50
- Resistance Level
- IFRX $2.74
- BETR $11.49
- Average True Range (ATR)
- IFRX 0.25
- BETR 0.78
- MACD
- IFRX -0.06
- BETR -0.20
- Stochastic Oscillator
- IFRX 34.88
- BETR 19.53
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.